Arcus Biosciences (RCUS) Net Equity Issued and Repurchased (2020 - 2025)

Arcus Biosciences' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $279.0 million for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $279.0 million in Q4 2025; TTM through Mar 2026 was $287.0 million, a 102.11% increase from a year earlier, with the FY2025 full-year figure at $429.0 million, up 88.16% from the prior year.
• Net Equity Issued and Repurchased advanced to $279.0 million in Q4 2025 per RCUS's latest filing, from $8.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $279.0 million in Q4 2025 and bottomed at -$235000.0 in Q4 2021.
• The 4-year median for Net Equity Issued and Repurchased is $81.0 million (2023), against an average of $112.8 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 34151.17% in 2021; the steepest drop was 204.91% in 2021.
• Year by year, Net Equity Issued and Repurchased stood at -$235000.0 in 2021, then surged by 2227.66% to $5.0 million in 2023, then surged by 4460.0% to $228.0 million in 2024, then increased by 22.37% to $279.0 million in 2025.
• Per Business Quant, the three latest RCUS Net Equity Issued and Repurchased figures stand at $279.0 million (Q4 2025), $8.0 million (Q3 2025), and $142.0 million (Q1 2025).